1998
DOI: 10.1128/aac.42.9.2456
|View full text |Cite
|
Sign up to set email alerts
|

Antimalarial Activities of Polyhydroxyphenyl and Hydroxamic Acid Derivatives

Abstract: Several known mammalian ribonucleotide reductase inhibitors featuring a polyhydroxyphenyl and/or hydroxamate moiety as the active group were screened for potency in inhibiting growth of the malaria parasite Plasmodium falciparum. Compounds containing a 2,3- or 3,4-dihydroxyphenyl group as well as benzohydroxamate appear to be the most effective inhibitors of the malaria parasite.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
26
0

Year Published

2002
2002
2013
2013

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 48 publications
(26 citation statements)
references
References 15 publications
0
26
0
Order By: Relevance
“…Similar structures to hydroxyurea [101] such as acetohydroxamate [102], substituted benzohydroxamic acids [54] or even hydroxylamine, hydroquinones and hydrazine derivatives [103] have shown similar inhibition behaviour. Although some of them are structurally dissimilar, they all readily donate electrons that facilitate the quenching of the critical tyrosyl radical.…”
Section: Specific R2 Binding Inhibitorsmentioning
confidence: 91%
See 1 more Smart Citation
“…Similar structures to hydroxyurea [101] such as acetohydroxamate [102], substituted benzohydroxamic acids [54] or even hydroxylamine, hydroquinones and hydrazine derivatives [103] have shown similar inhibition behaviour. Although some of them are structurally dissimilar, they all readily donate electrons that facilitate the quenching of the critical tyrosyl radical.…”
Section: Specific R2 Binding Inhibitorsmentioning
confidence: 91%
“…Most of these inhibitors are being tested in clinical trials and some of them have already been approved for the treatment of sickle cell anaemia and certain forms of cancer such as non-small cell lung cancer, adenocarcinoma of pancreas, bladder cancer, leukaemia and solid tumours [52]. Although less studied these inhibitors can also be used in anti-viral, anti-bacterial and anti-parasite therapies, and may be applied in the near future in the treatment of diseases such as AIDS [53] and malaria [54]. entire mRNA coding sequence.…”
Section: Scheme 1 Ribonucleotide Reduction Catalysed By Rnrmentioning
confidence: 98%
“…They are also capable of competing as siderophores for iron-(III) [9][10][11]. In the biomedical sciences, hydroxamic acids moieties are used in the design of therapeutics targeting cancer [12][13][14][15], cardiovascular diseases [16,17], HIV [18,19], Alzheimer's [20,21], malaria [22][23][24][25][26][27], allergic diseases [28][29][30], tuberculosis [31][32][33][34][35][36], metal poisoning [37][38][39][40], and ironoverload [41][42][43]. In addition, the hydroxamic acids have been employed as insecticides [44,45], antimicrobials [46][47][48][49][50][51][52][53], and plant growth regulators [54][55][56]…”
Section: Introductionmentioning
confidence: 99%
“…39 Retro-hydroxamate siderophores are analogues in which the position of the hydroxamate nitrogen and carbon are interchanged relative to their position in the natural siderophore and have found application as antimalarial agents. [40][41][42][43] The first synthetic analogues of hydroxamate siderophores based on methyl a-D-glucopyranoside, methyl a-D-galactopyranoside, methyl a-Dribopyranoside and methyl a-D-xylopyranoside were in fact retro-hydroxamates and were reported by Heggemann et al 15 The two hexoses were first protected with a trityl group at C-6, so that all four monosaccharides studied have only three free OH groups (OH-2, 3 and 4). The corresponding retro-trishydroxamates with different spacer groups were prepared by Steglich esterification with N-benzoyloxy-N-methylglutaric acid (30-33a), N-benzyloxy-N-methylsuccinic acid (30-33b), N-benzyloxy-N-methylglutaric acid (30-33c) and N-benzyloxy-N-butylglutaric acid (30d), using dicyclohexyl-carbodiimide (DCC) and N,N-dimethylaminopyridine (DMAP) in dichloromethane.…”
Section: Retro-hydroxamate and Hydroxamate Derivativesmentioning
confidence: 97%